Research programme: therapeutic antibodies - ShangPharma

Drug Profile

Research programme: therapeutic antibodies - ShangPharma

Alternative Names: H2L2 IgG; H2L2 IgG antibodies; Therapeutic antibodies - Harbour Antibodies/ShangPharma

Latest Information Update: 26 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ShangPharma
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Unspecified

Most Recent Events

  • 19 Dec 2016 Harbour Antibodies has been acquired by Harbour BioMed
  • 16 Jul 2016 No recent reports of development identified for research development in Undefined in China
  • 19 Dec 2014 Erasmus University Medical Center has patent protection for HCAb mouse platform in USA, Russia and South Africa
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top